What is ElevateBio?
Headquartered in Cambridge, Massachusetts, ElevateBio operates as a specialized platform for the creation and management of cell and gene therapy companies. By fostering deep partnerships with leading scientists and inventors, the company provides the necessary infrastructure, technology, and operational expertise to translate complex biological discoveries into viable clinical treatments. This portfolio-centric approach allows ElevateBio to mitigate the risks typically associated with early-stage biotech development while maximizing the potential for breakthrough medical innovations. The company's market position is defined by its ability to bridge the gap between academic research and commercial-scale manufacturing, effectively serving as a catalyst for the next generation of genetic medicine.
How much funding has ElevateBio raised?
ElevateBio has raised a total of $1.2B across 4 funding rounds:
Series A
$150M
Series B
$170M
Series C
$525M
Series D
$401M
Series A (2019): $150M with participation from EcoR1 Capital, Redmile Group, Samsara BioCapital, MPM Capital, F2 Ventures, and UBS Oncology Impact Fund
Series B (2020): $170M led by MPM Capital, F2 Ventures, Redmile Group, EDBI, Surveyor Capital, EcoR1 Capital, The Invus Group, Vertex Ventures, and Samsara BioCapital
Series C (2021): $525M supported by MPM Capital, F2 Ventures, Surveyor Capital, Samsara BioCapital, Fidelity, ITOCHU, Emerson Collective, SoftBank Group Corp., Redmile Group, EDBI, Vertex Ventures, EcoR1 Capital, Invus, and Matrix Capital Management Company
Series D (2023): $401M featuring Matrix Capital Management, Invus, Emerson Collective, and Woodline Partners
Key Investors in ElevateBio
Matrix Capital Management
Matrix Capital Management Company is an investment fund focused on technology and life sciences headquartered in Waltham, Massachusetts.
Invus Group
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
Emerson Collective
Emerson Collective is a company that invests in entrepreneurs and innovators who are driven by purpose and a sense of possibility, focusing on addressing complex challenges in education, economic mobility, and the environment.
What's next for ElevateBio?
Looking ahead, the strategic deployment of the $401M will likely focus on expanding the company's manufacturing footprint and enhancing its proprietary technology platforms. As ElevateBio matures, the focus will shift toward clinical execution and the successful commercialization of its pipeline assets. By leveraging its established network of partners and its deep bench of scientific talent, the company is well-positioned to navigate the complexities of the regulatory environment and address unmet medical needs. The continued support from its investor base suggests a long-term outlook centered on sustainable growth and the establishment of a dominant presence in the global cell and gene therapy market.
See full ElevateBio company page
